Alternative Options and Future Directions for Thyroid Cancer Therapy

Senolytics represent a group of mechanistically diverse drugs that can eliminate senescent cells, both in tumors and in several aging-related pathologies. Consequently, senolytic use has been proposed as a potential adjuvant approach to improve the response to senescence-inducing conventional and targeted cancer therapies. Despite the unequivocal promise of senolytics, issues of universality, selectivity, resistance, and toxicity remain to be further clarified. In this review, we attempt to summarize and analyze the current preclinical literature involving the use of senolytics in senescent tumor cell models, and to propose tenable solutions and future directions to improve the understanding and use of this novel class of drugs.

Download Full-text

Anticancer Drug Prescription Patterns in Japan: Future Directions in Cancer Therapy

Therapeutic Innovation & Regulatory Science ◽

10.1177/2168479017751404 ◽

2018 ◽

Vol 52 (6) ◽

pp. 718-723 ◽

Cited By ~ 5

Author(s):

Shoyo Shibata ◽

Maiko Matsushita ◽

Yoshimasa Saito ◽

Takeshi Suzuki

Keyword(s):

Cancer Therapy ◽

Anticancer Drug ◽

Drug Prescription ◽

Future Directions ◽

Prescription Patterns

Download Full-text

State of the art and future directions in the systemic treatment of medullary thyroid cancer

Current Opinion in Oncology ◽

10.1097/cco.0000000000000798 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Eline C. Jager ◽

K. Esther Broekman ◽

Schelto Kruijff ◽

Thera P. Links

Keyword(s):

Thyroid Cancer ◽

Medullary Thyroid Cancer ◽

Systemic Treatment ◽

State Of The Art ◽

Future Directions ◽

Medullary Thyroid

Download Full-text

Bacteria in cancer therapy: Strategies to improvement and future directions

New and Future Developments in Microbial Biotechnology and Bioengineering ◽

10.1016/b978-0-12-820528-0.00013-2 ◽

2020 ◽

pp. 191-202

Author(s):

Nafiseh Sadat Naghavi ◽

Mozhgan Ghiasian ◽

Faezeh Samieipour

Keyword(s):

Cancer Therapy ◽

Future Directions ◽

Therapy Strategies

Download Full-text

Dual-target kinase drug design: Current strategies and future directions in cancer therapy

European Journal of Medicinal Chemistry ◽

10.1016/j.ejmech.2019.112025 ◽

2020 ◽

Vol 188 ◽

pp. 112025 ◽

Cited By ~ 6

Author(s):

Dejuan Sun ◽

Yuqian Zhao ◽

Shouyue Zhang ◽

Lan Zhang ◽

Bo Liu ◽

...

Keyword(s):

Cancer Therapy ◽

Drug Design ◽

Future Directions ◽

Dual Target

Download Full-text

Abstract 2329: Clinical manufacturing of CAR T cells targeting ICAM-1 for a phase I study against advanced thyroid cancer therapy

10.1158/1538-7445.sabcs18-2329 ◽

2019 ◽

Author(s):

Yogindra Vedvyas ◽

Jaclyn E. McCloskey ◽

Yanping Yang ◽

Irene M. Min ◽

Thomas J. Fahey ◽

...

Keyword(s):

T Cells ◽

Thyroid Cancer ◽

Cancer Therapy ◽

Phase I ◽

Phase I Study ◽

Car T Cells ◽

Car T ◽

Advanced Thyroid Cancer

Download Full-text

Article Commentary: Medullary Thyroid Cancer: An Update for Surgeons

The American Surgeon ◽

10.1177/000313481508100102 ◽

2015 ◽

Vol 81 (1) ◽

pp. 1-8 ◽

Cited By ~ 9

Author(s):

Faris K. Azar ◽

Stephanie L. Lee ◽

Jennifer E. Rosen

Keyword(s):

Thyroid Cancer ◽

Thyroid Carcinoma ◽

Medullary Thyroid Carcinoma ◽

Progressive Disease ◽

Medullary Thyroid Cancer ◽

Germline Mutations ◽

Current Management ◽

Future Directions ◽

Medullary Thyroid ◽

Individualized Management

Medullary thyroid carcinoma is uncommon but accounts for approximately 4 to 5 per cent of all thyroid cancers. Although most cases are sporadic, close to one-fourth of cases result from germline mutations in the RET proto-oncogene. These mutations are clinically important because they predict the earliest age of medullary thyroid cancer diagnosis and clinical aggressiveness, which guide individualized management. This review covers the presentation, diagnosis, workup, current management, and future directions of the management of medullary thyroid carcinoma. Today's chance for cure depends on early and appropriate surgical resection. Further investigation of the cellular signaling pathways shown to be essential for the growth and spread of medullary thyroid carcinoma remains an active field with hope for providing targeted systemic therapy for patients with progressive disease.

Download Full-text